Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $13.80.

A number of research analysts have commented on OBIO shares. Wall Street Zen upgraded Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Barclays boosted their price target on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, March 12th. Finally, TD Cowen started coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating on the stock.

Insider Transactions at Orchestra BioMed

In other news, insider David P. Hochman acquired 10,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were purchased at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the acquisition, the insider directly owned 1,086,467 shares of the company’s stock, valued at $4,660,943.43. This represents a 0.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.10% of the stock is owned by company insiders.

Institutional Trading of Orchestra BioMed

A number of hedge funds and other institutional investors have recently modified their holdings of OBIO. AMH Equity Ltd purchased a new position in Orchestra BioMed in the third quarter valued at about $412,000. Catalyst Funds Management Pty Ltd acquired a new stake in Orchestra BioMed during the 2nd quarter valued at approximately $31,000. Balyasny Asset Management L.P. purchased a new stake in Orchestra BioMed during the 4th quarter worth approximately $76,000. Tower Research Capital LLC TRC raised its position in shares of Orchestra BioMed by 1,137.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 27,922 shares of the company’s stock valued at $75,000 after purchasing an additional 25,666 shares in the last quarter. Finally, Cresset Asset Management LLC acquired a new position in shares of Orchestra BioMed in the 3rd quarter valued at approximately $74,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Stock Down 2.2%

OBIO opened at $4.51 on Thursday. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42. The firm has a 50 day moving average price of $4.19 and a 200 day moving average price of $3.89. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45. The company has a market cap of $263.93 million, a PE ratio of -3.99 and a beta of 0.56.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings results on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.64. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The firm had revenue of $30.92 million for the quarter, compared to analysts’ expectations of $0.93 million. Sell-side analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.